Abstract Library

#4136 Peptide receptor radionuclide treatment in an outpatient setting – A single center experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is an important treatment option for somatostatin receptor expressing non-resectable neuroendocrine tumors. Traditionally, this therapy has been provided as inpatient care. PRRT has been offered by Oslo University Hospital from November 2019, and organized mainly as outpatient care.

Conference:

Presenting Author:

Authors: Sponheim J, Dahle V, Skrede Mordal K, Solberg H, Åvitsland T,

Keywords: PRRT, outpatient care,

#4042 177Lu-dotatate as salvage therapy in bronchial and GEP NET patients: The IRST "Dino Amadori" experience

Introduction: RLT with SSA represents a treatment of choice after progression from “cold” SSA analogues in NENs. After progression from RLT, other systemic treatments are used including a salvage therapy with RLT that is increasingly proposed.

Conference:

Presenting Author:

Authors: Sansovini M,

Keywords: Neuroendocrine tumor, salvage radioligand therapy,

#3762 Cabozantinib in high grade neuroendocrine neoplasms – Interim results from a Phase II trial

Introduction: Patients with high grade neuroendocrine neoplasms (HG-NENs) have limited treatment options. Cabozantinib, a multi kinase inhibitor can affect tumor growth and metastasis.

Conference:

Presenting Author: Trikalinos N

Authors: Trikalinos N, Pedersen K, Tan B, Amin M, Rama S,

Keywords: Cabozantinib, high-grade, neuroendocrine, neoplasm, clinical trial,

#3609 Interest of systematic resection of the visible scar, after incomplete endoscopic resection of rectal neuroendocrine tumors

Introduction: Rectal Neuroendocrine tumors (r-NET) can often be misidentified as diminutive polyps, leading to inappropriate resection technique. When the initial resection is not R0, the persistence of a local residue could lead to a disease recurrence.

Conference:

Presenting Author:

Authors: Cheminel L, Wallenhorst T, Lepilliez V, Jacques J, Abou Ali E,

Keywords: rectal neuroendocrine tumor, incomplete resection, endoscopy, salvage resection,

#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety

Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: SCALORBI F

Authors: Scalorbi F, Mazzaglia S, Maccauro M, Chiesa C, Prinzi N,

Keywords: prrt, healthy tissue and target lesion dosimetry, gastroenteropancreatic neuroendocrine tumor,